Published in Nat Biotechnol on March 30, 2008
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62
Thymic development beyond beta-selection requires phosphatidylinositol 3-kinase activation by CXCR4. J Exp Med (2009) 1.46
NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med (2009) 1.30
Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol (2012) 1.20
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. J Clin Invest (2008) 1.16
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood (2010) 1.01
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst (2010) 0.98
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest (2013) 0.96
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood (2008) 0.95
Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest (2012) 0.95
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
CD28z CARs and armored CARs. Cancer J (2014) 0.89
Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol (2008) 0.86
Human T-lymphoid progenitors generated in a feeder-cell-free Delta-like-4 culture system promote T-cell reconstitution in NOD/SCID/γc(-/-) mice. Stem Cells (2012) 0.84
Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation. Immunol Lett (2013) 0.82
Recombinant IL-7/HGFβ hybrid cytokine enhances T cell recovery in mice following allogeneic bone marrow transplantation. PLoS One (2013) 0.81
Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1. Nat Methods (2017) 0.81
Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2011) 0.80
Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol Rev (2014) 0.80
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. Mol Ther (2016) 0.79
Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. Semin Immunopathol (2008) 0.78
Thymus: the next (re)generation. Immunol Rev (2016) 0.78
In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination. Stem Cells (2015) 0.78
Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chin J Cancer (2015) 0.78
Inducible T-cell receptor expression in precursor T cells for leukemia control. Leukemia (2015) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Extra-thymic physiological T lineage progenitor activity is exclusively confined to cells expressing either CD127, CD90, or high levels of CD117. PLoS One (2012) 0.76
Notch signaling in hematopoietic cell transplantation and T cell alloimmunity. Blood Rev (2013) 0.76
Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Mol Ther (2016) 0.75
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther (2017) 0.75
Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J (2017) 0.75
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology (2017) 0.75
T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight (2017) 0.75
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity (2002) 8.17
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 6.26
Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003) 5.66
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood (1996) 4.65
Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood (1997) 4.51
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol (2004) 3.33
The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V beta 11-bearing T cells. J Exp Med (1989) 3.30
Haematopoietic cell transplantation as immunotherapy. Nature (2001) 2.88
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature (2000) 2.84
Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science (2002) 2.72
Lymphostromal interactions in thymic development and function. Nat Rev Immunol (2001) 2.44
Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2.41
Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive T cells. Science (1990) 2.25
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood (2006) 2.14
Thymic aging and T-cell regeneration. Immunol Rev (1997) 2.07
Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood (2004) 1.98
Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med (1996) 1.94
Superantigens of mouse mammary tumor virus. Annu Rev Immunol (1995) 1.86
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med (2006) 1.85
Inefficient positive selection of T cells directed by haematopoietic cells. Nature (1992) 1.84
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells. J Clin Invest (2002) 1.72
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant (2001) 1.67
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2005) 1.60
Donor T cells to treat EBV-associated lymphoma. N Engl J Med (1994) 1.53
CCR2 is required for CD8-induced graft-versus-host disease. Blood (2005) 1.43
Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia (2002) 1.42
Human bone marrow CD34+ progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus microenvironment. Blood Cells Mol Dis (2004) 1.39
Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma (2005) 1.30
Naturally occurring primary deficiencies of the immune system. Annu Rev Immunol (1997) 1.29
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 1.25
Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci U S A (2002) 1.22
Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol (2002) 1.16
Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant (2006) 1.15
Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood (2007) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
T/NK bipotent progenitors in the thymus retain the potential to generate dendritic cells. J Immunol (2003) 1.09
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest (1998) 1.08
Selective decreases in T cell receptor V beta expression. Decreased expression of specific V beta families is associated with expression of multiple MHC and non-MHC gene products. J Exp Med (1989) 1.08
Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant (2003) 1.01
Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol (1997) 0.93
Late T cell deficiency in victims of the Chernobyl radiation accident: possible mechanisms of induction. Int J Radiat Biol (1993) 0.93
Bone marrow-derived cells fail to induce positive selection in thymus reaggregation cultures. J Exp Med (1996) 0.92
Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hematol (2003) 0.92
Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res (2002) 0.90
Advances in basic and clinical immunology. J Allergy Clin Immunol (2006) 0.88
Characterization of a new minor lymphocyte stimulatory system. I. Cluster of self antigens recognized by "I-E-reactive" V beta s, V beta 5, V beta 11, and V beta 12 T cell receptors for antigen. J Immunol (1991) 0.84
Identification of lymphoma-associated antigens using SEREX. Methods Mol Med (2005) 0.84
Human T cell immunodeficiency: when signal transduction goes wrong. Immunol Res (2006) 0.78
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol (2009) 13.16
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity (2002) 8.17
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther (2010) 4.54
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res (2007) 4.42
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol (2005) 3.51
Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol (2004) 3.33
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol (2012) 3.28
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother (2009) 3.11
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Zoned out: functional mapping of stromal signaling microenvironments in the thymus. Annu Rev Immunol (2007) 2.98
Interleukin-22 drives endogenous thymic regeneration in mice. Science (2012) 2.96
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A (2009) 2.86
CARs on track in the clinic. Mol Ther (2011) 2.86
Heterogeneity among DN1 prothymocytes reveals multiple progenitors with different capacities to generate T cell and non-T cell lineages. Immunity (2004) 2.84
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood (2010) 2.73
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73
Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2012) 2.72
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2011) 2.68
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci U S A (2010) 2.67
Maintenance of T cell specification and differentiation requires recurrent notch receptor-ligand interactions. J Exp Med (2004) 2.58
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Commitment and developmental potential of extrathymic and intrathymic T cell precursors: plenty to choose from. Immunity (2007) 2.51
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol (2010) 2.43
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Pakistan's reform experiment. Nature (2009) 2.35
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell (2011) 2.33
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol (2012) 2.26
Innate immune activation and CD4+ T cell priming during respiratory fungal infection. Immunity (2006) 2.20
Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J Immunol (2004) 2.18
Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol (2011) 2.17
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol (2007) 2.12
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer (2003) 2.08
gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood (2009) 2.07
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol (2006) 1.99
T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep (2012) 1.99
Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood (2004) 1.98
Delayed, asynchronous, and reversible T-lineage specification induced by Notch/Delta signaling. Genes Dev (2005) 1.98
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med (2009) 1.98
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
T-cell therapy at the threshold. Nat Biotechnol (2012) 1.91
Thymic involution and immune reconstitution. Trends Immunol (2009) 1.91
Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse (2005) 1.90
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood (2002) 1.89
Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood (2012) 1.87